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recurrent, debilitating abdominal pain, usually occurring within
the ﬁrst hour after meals. Hence its been also referred to as
intestinal angina.3 This is due to insufﬁcient visceral blood ﬂow
during periods of heightened intestinal demands.4 Therapeutic
options include surgical reconstruction and percutaneous trans-
luminal angioplasty (PTA) with or without stent placement.5 PTA
has become an alternative to surgery in many high risk surgical
patients. The procedural and clinical success rate of PTA has been
reported to be greater than 80% and 75%, respectively.6–8 In PTA
without stenting, restenosis of the dilated artery and recurrence of
symptoms occur in 17–50% of patients within the ﬁrst year.6–8 This
reduces the efﬁcacy and durability of balloon angioplasty. Matsu-
moto et al. reported from his case series comparing PTA with and
without stenting, that PTAwith stentingwas associatedwith lower
incidence of complications and a higher technical and clinical
success rate.9 We report our patient who was initially diagnosed
as a case of acid peptic disease (APD) and later as postprandial
angina secondary to coronary ischemia. Our patient actually had
SMA stenosis and occlusion presenting as APD and postprandial
angina. Patient successfully underwent PTA with stenting with
dramatic improvement. His 2 yrs follow-up with upper GI endo-
scopy showed normal gastroduodenal mucosa.
Conclusion: SMA stenosis, a rare condition, presents as recurrent
abdominal pain with postprandial angina, should be carefully
considered because of its serious clinical consequences. PTA with
stenting has been considered as a safe and effective treatment
alternative to surgery.
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Introduction: Clopidrogel is the most common, cost effective med-
ication available for patients undergoing PCI. But variations in
CYP2C19 has been associated in decreasedmetabolism of this drug
leading to MACE. The other anti-platelet drugs considered in such
situations include Prasugrel and Ticagrelor, which are highly efﬁ-
cient when compared to Clopidrogel but are sometimes associated
with bleeding andTicagrelor is expensive. CYP2C19*2/*3 is themost
common, loss of function mutation in this gene, which reduces its
activity and hence lowmetabolism of Clopidrogel. Patients hetero-
zygous to anyone of these SNPs have to be put on alternative
treatment regime, which included Prasugrel and Ticagrelor or
higher doses of Clopidrogel.
Objective: To evaluate the efﬁciency of Clopidrogel (75 mg), Prasu-
grel (10 mg) and Ticagrelor (90 mg) in PCI patients heterozygous for
CYP2C19*2/*3.
Methodology: A total of 20 patients who have undergone PCI and
heterozygous for CYP2C19*2 and CYP2C19*3 variations were
recruited fromSri Balaji Hospital, Chrompet after obtainingwritten
informed consent. The patients were randomly categorized into 3
regimens: double dose Clopidrogel (75 mg), Prasugrel (10 mg), and
Ticagrelor (90 mg). Each group has 8, 8, and 4 patients, respectively.
The efﬁcacy of these drugs was evaluated by platelet response
array using FACS. Based on platelet reactivity index (PRI), theywere
classiﬁed as normal (<50), borderline, or poor (>50) response.
Results: Of the 8 patients who had Clopidrogel (75 mg), two had
borderline response and the rest 6 had poor response, and of
the 8 patients, who were on Prasugrel (10 mg), two had borderline
and 6 had good response. The 4 patients on Ticagrelor had good
response.
Conclusion: Evaluation of the efﬁcacy of these three anti-platelet
drugs in the heterozygous group of CYP2C19*2/*3 showed Ticagre-
lor is highly efﬁcient in preventing platelet aggregation followed by
Prasugrel in our cohort. Patients on double dose Clopidogrel have
high residual platelet reactivity.
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Back ground: Clopidogrel is an prodrug that requires hepatic
bioactivation by several enzymes including CYP2C19. Clopidogrel,
which is currently the mainstay of management after PCI, fails in
certain group of individuals, as they are unable to metabolize the
drug. Variations in the gene CYP2C19 has been associated with
poor metabolism of clopidogrel and hence mace
Methods: A total of 151 patients who have undergone PCI were
recruited from our institution after obtaining written informed
consent. Salivary samples from patients were genotyped for
CYP2C19*2, CYP2C19*3 variations by sequencing method (GAAP
X METHOD). Dual antiplatelets were given based on genotype
information.
Results: Based on their genotyping result for CYP2C19*2 and
CYP2C19*3, patients were categorized into 3 groups – normal
(GG,GG), intermediate (AG), and poor (homozygous variant AA).
Percentage of individuals in each group was 29, 52, and 19, respec-
tively. Poor metabolizers were given newer agents (Prasugrel or
Ticagrelor). Intermediate metabolizers were given newer agents or
double dose clopidogrel. Out of 151 patients followed-up for 6
months, only 3 patients (1.5%) were admitted with myocardial
infarction (troponin positive). They all underwent CAG – one
patient had stent thrombosis. He was not compliant with anti-
platelets. Other two had lesions in non-culprit vessels with patent
stents.
Conclusion: Major adverse coronary events after PCI were brought
down signiﬁcantly by genotyping individuals. Genotype may be
relevant for choosing appropriate dual antiplatelet therapy in
patients undergoing PCI.
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Absorb biodegradable biovascular scaffold (BVS) is a relatively new
device in themanagement of coronary artery disease. Initially, BVS
was studied in chronic stable lesions. There is emerging data on its
usage in acute coronary syndrome lesion. Themanufacturer advo-
cates 5 Ps during deployment of the scaffold (proper sizing, pre-
dilatation, pay attention to expansion limit, post dilation with
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